BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
PR Newswire•31/08/2026•07:00 ET
0
Whiz Insights
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September -
Get started
Create a free account to read the full story.